Synapse - Paul Paik

Search Within

Paul K Paik

Results (256)

Microsatellite instability and mismatch repair deficiency define a distinct subset of lung cancers characterized by smoking exposure, high tumor mutational burden, and recurrent somatic MLH1 inactivation

Journal Article

Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D. A.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benayed, R.; more...
Journal of Thoracic Oncology (2024)

Fulltext@MSK | Save

Orthogonal testing unravels a novel ROS1 Oncogenic Fusion Variant (ROS1-GPM6A): A practical approach to molecular testing for actionable fusion variants

Journal Article

Narvel, H. G.; Kim, S. Y.; Shokrekhuda, A. M.; Cohen, P. R.; Ramesh, K. H.; Solomon, S. R.; Paik, P. K.; Halmos, B.
JCO Precision Oncology (2023)

Fulltext@MSK | Save

Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States

Journal Article

Yang, M.; MacEwan, J. P.; Boppudi, S. S.; McClain, M. R.; O'Hara, R. M. Jr; Paik, P. K.
Cancer Medicine (2023)

Fulltext@MSK | Save

Treatment (Tx) sequencing with tepotinib in previously treated patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION trial

Meeting Abstract

Viteri, S.; Felip, E.; Griesinger, F.; Garassino, M. C.; Sakai, H.; Le, X.; Veillon, R.; Smit, E. F.; Raskin, J.; Thomas, M.; more...
Annals of Oncology (2023)

Fulltext@MSK | Save

Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib

Meeting Abstract

Rolfo, C. D.; Grupp, A. M. O.; Menzel, C.; Bruns, R.; Juraeva, D.; Stroh, C.; Johne, A.; Paik, P. K.
Annals of Oncology (2023)

Fulltext@MSK | Save

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

Journal Article

Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Galvez, C. C.; Smit, E. F.; Garassino, M.; Veillon, R.; Baz, D. V.; Pradera, J. F.; more...
Cell Reports Medicine (2023)

Fulltext@MSK | Save

ctDNA dynamics, prognostic markers, and mechanisms of resistance in tepotinib-treated MET exon 14 (METex14) skipping NSCLC in the VISION trial

Meeting Abstract

Xiuning, L.; Garassino, M. C.; Ahn, M . J.; Felip, E.; Cortot, A. B.; Hiroshi, S.; Mazières, J.; Thomas, M.; Viteri, S.; Conte, P.; more...
Journal of Oncology Navigation & Survivorship (2023)

Fulltext@MSK | Save

Tepotinib and capmatinib in patients with MET exon 14 skipping NSCLC: A matching adjusted indirect comparison (MAIC)

Meeting Abstract

Pfeiffer, B. M.; Postma, M. J.; Hatswell, A.; Vioix, H.; Paik, P. K.
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save

Tepotinib in Asian patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in long-term follow-up from VISION

Meeting Abstract

Ahn, M. J.; Kato, T.; Yang, J. C. H.; Sakai, H.; Morise, M.; Chen, Y. M.; Han, J. Y.; Yang, J. J.; Zhao, J.; Hsia, T. C.; more...
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save

Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation

Meeting Abstract

Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
Journal of Thoracic Oncology (2023)

Fulltext@MSK | Save